CP therapy might be a confident strategy choice for COVID-19 saving.
•
Tocilizumab and Anakinra have shown some benefits in patients with COVID-19.
•
Recent findings show that the HQC has no beneficial effects on COVID-19 patients.
•
hrsACE2, Ivermectin, and EIDD-2801 have exhibited an inhibitory effect against SARS-CoV-2.
•
Recent data show that the only remdesivir has a limited benefit in patients with COVID-19.
Abstract
The SARS-CoV-2 virus is an etiological agent of pandemic COVID-19, which spreads rapidly worldwide. No proven effective therapies currently exist for this virus, and efforts to develop antiviral strategies for the treatment of COVID-19 are underway. The rapidly increasing understanding of SARS-CoV-2 virology provides a notable number of possible immunological procedures and drug targets. However, gaps remain in our understanding of the pathogenesis of COVID-19. In this review, we describe the latest information in the context of immunological approaches and emerging current antiviral strategies for COVID-19 treatment.